Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers

What is the efficacy of nivolumab and ipilimumab combination treatment in patients with advanced mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) noncolorectal cancers?In this phase 2 nonrandomized clinical trial including 52 patients with dMMR/MSI-H noncolorectal cancers, an objective response rate of 63% and a 6-month progression-free survival of 71% was observed.Nivolumab and ipilimumab showed significant activity in dMMR/MSI-H noncolorectal cancers and represent a treatment option besides anti–programmed cell death 1 monotherapy.

Corresponding Author: Oliver Klein, MD, Olivia Newton-John Cancer Research Institute, Austin Health,145 Studley Rd, Heidelberg VIC 3084, Australia (oliver.klein@onjcri.org.au).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.